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OXIDATION STATUS AS A PREDICTOR OF DISEASE ACTIVITY AND 
RESPONSE TO THERAPY IN PEDIATRIC PATIENTS WITH 
INFLAMMATORY BOWEL DISEASE 
NATHAN L. WEINBREN 
ABSTRACT 
INTRODUCTION: Physiologic and pathophysiologic inflammation is mediated, at least 
in part, by the generation and  release of reactive oxygen species into the local tissue 
milieu. The chronic inflammation observed in patients with inflammatory bowel disease 
(IBD) is thought to begin in the lining of the intestine and may progress to involve the 
entire bowel wall.In an effort to assess disease activity,  clinicians rely on  costly and 
technically invasive procedures such as colonoscopies. As such, there is currently a need 
for the development of less invasive and more cost-effective methods for use in the 
diagnosis and interval assessment of children and adults with these chronic intestinal 
inflammatory disorders. 
OBJECTIVES: The objective of this study was to first determine if ambient redox status 
can be reliably measured in the stool of patients with IBD. A second aim of the study was 
to determine if ambient stool redox status was related to underlying diagnosis, clinical 
disease activity, or response to therapy in patients with IBD .  
METHODS: We first our ability to measure redox redox standards using three different 
commercially available devices.  Once demonstrated, we then the process of performing 
sample analysis under various conditions (room tempererture, refrigerated, frozen, or 
spun/unspun) to determine the conditions under which we were able to achieve the most 
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stable redox assessments.  Finally, we conducted a small pilot cohort study in 
hospitalized pediatric patients with IBD to assess if stool redox status informed about 
disease activityWe collected stool samples from  seven patients admitted to the inpatient 
gastrointestinal service at Boston Children’s Hospital during a period extending from  
November of 2018 to March of 2019.  
RESULTS: Preliminary studies confirmed our ability to accurately measure relative 
redox status (RRS) using three different apparatuses. Furthermore, we were able to 
generate dilution curves using juices known to include oxidants, with linear regression r2 
values of 0.99. In our patient population, we confirmed our ability to generate a reliable 
readings and  consistent RRS measurements over. Frozen samples displayed less stable 
and higher RRS than those either refrigerated or kept at room temperature for up to 8-
hours.  This suggests that freeze-thaw cycles may impact adversely on the stability of 
oxidants and antioxidants in our samples.  The RRS measurements from stool samples 
collected from patients who were exhibiting active symptoms of their IBD measured 
about -400 mV, while  samples collected from hospitalized patients without IBD manifest 
RRS readings of  about 100 mV. 
CONCLUSION: This preliminary study demonstrates our ability to measure RRS in the 
stool of patients with and without IBD. The stability we observed in samples that were 
either stored at room temperature or refrigerated demonstrated that these represented 
optimal  storage options. Additionally, measurements from homogenized stool samples 
appeared to be more  variable when compared to the relatively smaller range from 
centrifuged samples. Initial studies indicated a strong difference in RRS measurements 
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between patients with inflammatory and non-inflammatory GI disease or inactive IBD. 
This difference suggests that measurements of RRS could provide a quantitative real-time 
assessments of disease activity and response to therapy in patients with IBD. 
  
  viii 
TABLE OF CONTENTS 
TITLE……………………………………………………………………………………...i 
COPYRIGHT PAGE……………………………………………………………………...ii 
READER APPROVAL PAGE………………………………………………………?…..iii 
ACKNOWLEDGMENTS ..............................................................................................iv 
ABSTRACT .................................................................................................................... v 
TABLE OF CONTENTS............................................................................................. viii 
LIST OF TABLES .......................................................................................................... x 
LIST OF FIGURES ........................................................................................................xi 
LIST OF ABBREVIATIONS ....................................................................................... xii 
INTRODUCTION ........................................................................................................... 1 
Inflammatory Bowel Diseases ............................................................................... 1 
Oxidative Stress and Reactive Oxygen Species ..................................................... 2 
Specific Aims and Objectives ................................................................................ 5 
MATERIALS AND METHODS ..................................................................................... 7 
Study Design .......................................................................................................... 7 
Redox Measuring Equipment ................................................................................ 7 
Patient Population Selection .................................................................................. 8 
Sample Preparation ............................................................................................... 9 
Initial Measurements ........................................................................................... 10 
  ix 
Patient-Related Measurements ........................................................................... 11 
RESULTS ..................................................................................................................... 16 
Patient Enrollment ............................................................................................... 16 
Initial Measurement Ability, Accuracy, and Reliability..................................... 17 
Measurements of Stool Samples Stored at Room Temperature ........................ 23 
Measurements of Stool Samples Stored in Refrigerated Conditions ................. 25 
Measurements of Frozen Stool Samples ............................................................. 27 
Analysis of Freezing Effects................................................................................. 29 
Analysis of Centrifuge Effects ............................................................................. 31 
Pediatric Ulcerative Colitis Activity Index (PUCAI) Scores .............................. 33 
DISCUSSION ............................................................................................................... 35 
CONCLUSION ............................................................................................................. 39 
Appendix A: Slopes and Y-Intercepts of Oxidant-Rich Sources ..................................... 40 
Appendix B: Room Temperature vs. Frozen Storage By Patient Over Time ................... 41 
Appendix C: Dietary Questionnaire ............................................................................... 49 
REFERENCES .............................................................................................................. 54 
CURRICULUM VITAE ................................................................................................ 57 
 
  x 
LIST OF TABLES 
 
 
Table Title Page 
1 Pediatric Ulcerative Colitis Activity Index 13 
2 Pediatric Crohn’s Disease Activity Index 14-15 
3 Linear Regression 21 
4 Patient Disease Values 34 
   
   
 
 
  
  xi 
LIST OF FIGURES 
 
 
 
Figure Title Page 
1 General Sources and Results of ROS 3 
2 Flowchart Explanation of Division and Preparation of 
Patient Samples 
10 
3 Flowchart of Patient Recruitment 17 
4 Standard Measurements Using Redox Probes 18 
5 Oxidant-Rich Juice Dilution Curves  19-20 
6 Comparing the Arrowdox and PCE Probes 23 
7 Measurement of Room Temperature Patient Samples 
Over Time 
24 
8 Measurement of Refrigerated Patient Samples Over Time 25 
9 Measurement of Frozen Patient Samples Over Time 28 
10 Effects of Freezing on Patient Sample Measurements 30 
11 Effects of Centrifugation on Patient Sample 
Measurements  
32 
 
 
  
 xii 
LIST OF ABBREVIATIONS 
CD................................................................................................................ Crohn’s Disease 
IBD.......................................................................................... Inflammatory Bowel Disease 
IC....................................................................................................... Indeterminate Crohn’s 
GI................................................................................................................ Gastroenterology 
NO...................................................................................................................... Nitric Oxide 
PCDAI.................................................................. Pediatric Crohn’s Disease Activity Index 
PUCAI................................................................ Pediatric Ulcerative Colitis Activity Index 
ROS............................................................................................... Reactive Oxygen Species 
RRS.................................................................................................... Relative Redox Status 
UC.............................................................................................................. Ulcerative Colitis 
 
 1 
INTRODUCTION 
Inflammatory Bowel Diseases 
Inflammatory bowel diseases (IBD) are characterized by the presence of  
inflammation within the mucosa of the gastrointestinal tract. There are two main 
classifications of this disease, Crohn Disease (CD) and ulcerative colitis (UC). Both 
forms of IBD are typified by cycles of relapsing and remitting disease activity. The 
inflammation observed in patients with CD can be patchy and occur in any region of the 
GI tract, beginning in the mouth and extending to the anus. In contrast the inflammation 
observed in patients with UC typically begins in the rectum and extends, in a contiguous 
fashion to involve either part or all of the large intestine1. Patients with Indeterminate 
Colitis (IC) have clinical signs and symptoms that overlap, and thereby preclude a more 
definitive CD or UC disease assignment. IBD is a growing public health concern, with 
incidence and prevalence of IBD on the rise in most regions of the world 2. Pediatrics 
have also seen an increase in prevalence; a study of Scottish incidence of IBD observed a 
66% rise in children diagnosed with CD between 1995 and 2008.3 
 As of 2019, the mechanism(s) underlying the pathogenesis of IBD remains 
unclear.  Existing data suggest that a number of  factors including genetics, 
environmental influence, and infectious agents all seem to be playing a role.3 This lack of 
a uniform mechanism of action further complicates the picture and hinders the 
development of consensus in-vitro and in-vivo disease models that enable researchers to 
study pathogenic regulators of disease activity as well newer treatment options. In the 
absence of a universally accepted disease model, different research groups base their 
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findings on various and disparate models based on genetic manipulation, environmental 
exposure, and toxin-mediated disease.1  
 
Oxidative Stress and Reactive Oxygen Species 
 While the complete pathogenetic picture contributing to the development of  IBD 
remains a work in progress, a number of factors have been implicated in the onset and 
propagation of the inflammatory response observed in these chronic diseases.1 Oxidative 
stress, a relative abundance of oxidant to anti-oxidant species in the local milieu, 
characterized tissue specimens taken from inflamed intestinal tissue.4 A recent study 
testing the efficacy a novel genetic approach to treatment of IBD in an animal model used 
a measure of  oxidative stress as study endpoint.2 Infection is typically accompanied by 
oxidative stress products, the most common of which are reactive oxygen species (ROS).  
Oxidant stress in the body can be assessed using serologic measures including lipid 
peroxidation and expression of redox enzymes like nitric sxide synthase and xanthine 
oxidase.4 These reactant generated by these enzymatic are highly reactive and can cause 
damage to native tissue as their ambient concentration rise unchecked by anti-oxidant 
mediators and signaling pathways.1 
Activated immune cells in the small and large intestine have evolved to release 
ROS as an innate defense against invading or circulating pathogens.  However, chronic 
an unregulated release of ROS, such as that occurring in active IBD can result in local 
tissue damage, including mucosal breakdown and epithelial apoptosis, as depicted in 
Figure 1.1  
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Figure 1. General Sources and Results of ROS This flow chart represents both the 
sources of Oxidative Stress and its corresponding reactants, including ROS, and relevant 
signaling pathways.1 
 
Interesting, the effects of ROS may be dose-dependent and at lower levels 
reactive species likely play an anti-inflammatory role. There is now evidence that in 
patients with CD epithelial mitochondria release ROS as a potential remedy for 
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inflammation, and only when the levels rise to pathologic levels do the ROS reactants 
become harmful5. In fact, disease recurrence following a period of remission coincides 
with an increase in ROS levels.6 
Therefore, it is proposed that it isn’t the presence of these ROS but an imbalance 
between ROS and competing antioxidant levels that leads to tissue damage. In a study 
consistent with this hypothesis, patients with IBD were observed to display increased 
ROS production as well as significantly decreased levels of antioxidants in their blood. 
This depletion of antioxidants likely resulted in an an imbalance in the physiologic 
equilibrium. As the mucosa of patients with IBD enter a state of oxidative stress and 
increased ambient  ROS, the body attempts to compensate by shifting some of its 
antioxidants to help lower the redox reactant concentration. However, inflammatory 
disease progression leads to even higher levels of ROS, for which the body cannot 
compensate due to the already depleted levels of antioxidants. This redox imbalance 
contributes to  ongoing tissue damage.7   
 Thus, targeting this oxidant/anti-oxidant imbalance could represent a new 
approach to the management of IBD. A recent study analyzing different antioxidant 
therapies in the treatment of patients with IBD found small, if inconclusive benefits. The 
authors went on to suggest that this form of neutraceutical therapy is likely most effective 
as one component of a broader pharmacologic approach. Studies looking at delivering 
compositive antioxidant therapy through a prescribed diet could lead to broader shifts and 
supports to the body’s own defensive mechanisms, whereas a more narrow scope  
pharmaceutical therapy might be less beneficial. They suggest that dietary maintenance 
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rich in antioxidants to supplement the immune system could even help maintain disease 
remission.6   
 There is also evidence to suggest gut-derived redox reactants can lead to tissue 
damage elsewhere in the body of patients with IBD. Pulmonary function was shown to be 
affected in pediatric patients presenting with CD. Their lungs presented with distinctly 
difficusion capacity of gases, including nitric oxide (NO), with a lower capacity in 
patients with IBD. Increased NO synthase levels were observed in the gut of patients with 
IBD and an increased release of NO (a known vasodilator4) can subsequently mediate 
increased dilation in other vessels, resulting in a net reduction in blood flow to the veins 
including pulmonary capillaries8,9. Decreased NO diffusion contributes to higher 
concentrations in the blood, and because NO can contribute to oxidative stress, this could 
lead to further oxidative complications. Henceoxidative imbalance within the 
gastrointestinal tract are not contained to that location. Further studies are needed to 
better understand how this oxidative effect might affect other regions of the body. 
 
Specific Aims and Objectives 
Anti-oxidants have often been discussed as a potential approach to IBD treatment.  
However, identification of the most relevant oxidant species has been elusive, and the 
ability to quantitate the dose-response relationship of antioxidants has slowed 
tremendously the development of this line of therapy. As such, the preliminary aim of 
this study was to demonstrate that redox status could be assessed in standards and 
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relevant biological fluids.  Once completed, we developed study conditions that would 
enable us to reliably measure relative redox status (RRS) in clinical (stool) samples. As 
the papers cited here have not utilized these tools for IBD research and especially not for 
stool studies, this initial step is very important to the viability of the study. 
The second the goal of the study is to recruit and enroll patients at Boston 
Children’s Hospital to enable a comparison of RRS in the stool of patients with and 
without inflammatory GI disease.  We hypothesize that the presence of ambient oxidative 
mediators (the results of acute and chronic inflammation) will result in measureable and 
significant differences in RSS in patients with active and inactive IBD. If our hypothesis 
is correct, the hope is that this technology can be leveraged for the development of further 
non-invasive, quantitative tests to assist in assessing  disease progression, response to 
therapy, and risk stratification/disease prognosis. RRS data from enrolled patients  will be 
compared with parallel disease status test results abstracted from the electronic medical 
record.  Future studies will include a standardized approach to the measurement of RRS 
in the  blood and stool patients with IBD. 
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MATERIALS AND METHODS 
Study Design 
This is an ongoing prospective cohort study of children admitted to Boston 
Children’s Hospital. We received approval from the Institutional Review Board (IRB) to 
approach all patients admitted and diagnosed with IBD, and enroll those who agree to 
participate by signing a consent form detailing the perameters of the study. 
 
Redox Measuring Equipment 
Three different probes were used to measure redox reactants in patient samples.  
Arrowdox is made by Shelfscientific, a division of Lazar Research Laboratories. 
The micro electrode measurement probe ORP-146S contains a  filling solution of 
potassium chloride.  Air bubbles are removed to ensure a continuous current flow and 
consistent readings. Before use, the electrode tip is dipped into a solution containing 5 M 
nitric acid for 30 seconds, and then flushed with distilled water. It is then treated with  a 
protein cleaning solution, Biotrue, from Bausch & LOMB. The probe is then connected 
to an electrometer, Lazar Model 6230.  
PCE ORP-14 is commercially available from PCE Instruments™. The PCE 
probe comes pre-filled with a potassium chloride solution. The PCE probe is cleaned 
using Biotrue, similar to the protocol used for the  Arrowdox system. The PCE probe is 
then connected to the PCE-228-R meter.  
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Redoxsys is a patented assay made available from  Aytu BioScience. There is no 
hand-held probe for the Redoxsys analyzer.  Instead, this technology relies on the of a 
single-use disposable Redoxsys sensor on which is placed 30 µL of patient sample prior 
to insertion  into the Redoxsys Analyzer. Once engaged, the device will read the RRS of 
the sample in approximately four minutes. 
 
Patient Population Selection 
 Patients were eligble for participation in the study if they were admitted to Boston 
Children’s Hospital on the Gastroenterology Service. Recruitment of initial samples was 
carried out variably during a period extending from November of 2018 and extending 
through March of 2019. The staggered recruitment was related to our iterative efforts to 
develop optimal storage and performance study conditions.  There were no exclusion 
criteria for pediatric and adolescent patients with IBD in this pilot study. 
 The available of fresh stool samples also limited initial study progress. There is no 
prior description of optimal sample collection or transport/storage conditions.  For this 
reason, we chose to restrict our initial conditions to study only fresh and 
unstored/unrefrigerated samples.  Though it limited sample aquisition, we felt that real 
time sample collection would result in the most reliable results for use in determining 
optimal performance standards. Therefore, patient samples were initially rejected if they 
were more than 1-2 hours old.   
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Sample Preparation 
 Collected samples were  homogenized and twenty-seven 1.5 µL aliquots were 
allocated for study. The remainder of the sample was then split into three, one of which 
was stored at room temperature, one was refrigerated, and one was frozen. Nine aliquoted 
samples were used for each of the room temperature, refrigeration, and freezing 
conditions. Aliquoted samples were then spun at 12,000 rpm for 5 minutes. The 
supernatant was collected and nine supernatants were mixed into three contaiers. The 
tubes were then spun for an additional minute at 12,000 rpm and supernatant collected 
and mixed into the three groups. Durring this process the solid portion of the stool 
separates from the liquid and forms a pellet at the bottom of the tube. The supernatant is 
then carefully removed without disturbing the solid pellet. Figure 2 reflects this sample 
preparation. 
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Figure 2: Flowchart Explanation of Division and Preparation of Patient Samples 
 
Initial Measurements 
 We chose to measure commercially available redox standards and store bought 
juices as an initial proof of concept and to demonstrate our ability to make consistent 
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redox measurements. The standards were purchased from PCE Instruments and included  
two standards: Standard A was calibrated to 240 mV and Standard B was calibrated to be 
468 mV. There was not a negative standard available. We utilized all three measurement 
systems to measure the standards.  
 Serial dilution curves of orange, apple, and cranberry and hydrogen peroxide were 
created for use in the study. Dilutions were made with distilled water using a dilution 
ratio of 1:2, beginning with straight sample and ending with 1:8. Serial dilution 
measurement were conducted using both the Arrowdox and PCE probes. 
 
Patient-Related Measurements 
 For this initial study of patient samples, we used the Arrowdox and PCE systems 
to measure patient samples. Probes were dipped into the sample and recorded once the 
meter generated a stable reading. Each sample was measured three times. At the 
beginning of each week, probes were re-calibrated using commercial standard solutions  
to ensure that accurate readings were obtained to ensure. While the calibration did not 
change, this step was done to ensure consistency in measurements. 
 Patient-specific data was abstracted from  the electronic medical records and 
stored on Microsoft Excel and Word data entry templates under password protection and 
behind the Boston Children’s Hospital digital firewall. Enrollment forms were completed 
in real time and filed in a locked location in the Center for Inflammatory Bowel Disease. 
Enrolled patients received unlinked sequential number assignments (i.e. Patient 1, 2, 3, 
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etc.), and this identifier was used in all subsequent data manipulation and analysis to 
ensure confidentiality. 
 Patient disease status was measured quantitatively in the clinic using  either the 
Pediatric Ulcerative Colitis Activity Index (PUCAI) or Pediatric Crohns’ Disease 
Activity Index (PCDAI). These measurements are perfomed by clinical care team and 
obtained via electronic records.These metrics were developed as a way to standardize 
clinical assessment and to stratify patients by disease activity and response to therapy. 
Table 1 reflects the grading for the PUCAI. These scores reflect six key catagories of 
active UC diagnosis: abdominal pain, rectal bleeding, stool consistency, number of stools 
per day, nocturnal activity, and relative activity.10 PUCAI scores range from 0-85 and 
active disease is defined as a PUCAI score > 10.10  
Table 2 reflects the grading for the PCDAI. Its metrics include history of 
abdominal pain, stool, and general function, in addition to quantitative measures like 
laboratory values and measurements taking upon examination. PCDAI scores range from 
0-100 and active CD is defined as a PCDAI score of > 11.11 
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Item Points 
Abdominal Pain 
No Pain 0 
Pain can be ignored 5 
Pain cannot be ignored 10 
Rectal Bleeding 
None 0 
Small amount only in < 50% of stool 10 
Small amount with most stools 20 
Large amount (> 50% of stool content) 30 
Stool Consistency of Most Stools 
Formed 0 
Partially formed 5 
Completely unformed 10 
Number of Stools Per 24 Hours 
0-2 0 
3-5 5 
6-8 10 
> 8 15 
Nocturnal Stools (Any Episode Causing Waking) 
No 0 
Yes 10 
Activity Level 
No limitation of activity 0 
Occasional Limitation of Activity 5 
Severe Restricted Activity 10 
Total Maximum Score 85 
Total Sum:  
Table 1: The Pediatric Ulcerative Colitis Activity Index (PUCAI)10  
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Item Points 
History (Recall, 1 Week) 
Abdominal Pain 
None 0 
Mild/brief/does not interfere with activities 5 
Moderate/severe/daily, longer lasting, affects 
activities, nocturnal 
10 
Stools (Per Day) 
No limitation of activities/well 0 
Occassional difficulty in maintaining age-appropriate 
activities/below par 
5 
Frequent limitation of activity/very poor 10 
Patient Functioning, General Well-Being 
0-1 liquid stools, no blood 0 
Up to 2 semiformed with small blood, or 2-5 liquid 5 
Gross bleeding, or > 5 liquid, or nocturnal diarrhea 10 
Laboratory 
Hematocrit 
< 10 (Male/Female) 11-14 (Male) 11-19 (Female) 15-19 (Male) 
>33% 0 >34% 0 >33% 0 >36% 0 
28-32% 2.5 30-34% 2.5 29-33% 2.5 32-36% 2.5 
<28% 5 <30% 5 <29% 5 <32% 5 
Erythrocyte Sedimentation Rate 
< 20 mm/hr 0 
20-50 mm/hr 2.5 
> 50 mm/hr 5 
Albumin 
> 3.4 g/dL 0 
3.1-3.4 g/dL 5 
<3.1 g/dL 10 
Examination 
Weight 
Weight gain or voluntary weight stable/loss 0 
Involuntary weight stable/weight loss 1-9% 5 
Weight loss > 10% 10 
Height 
< 1 channel decrease 0 
> 1, < 2 channel decrease 5 
> 2 channel decrease 10 
Height at Follow-Up Visit 
Height velocity > 1 SD 0 
Heigh velocity < 1 SD > 2 SD 5 
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Heigh Velocity < 2 SD 10 
Abdominal Exam 
No tenderness, no mass 0 
Tenderness or mass without tenderness 5 
Tenderness involuntary guarding, definite mass 10 
Perirectal Disease 
None, asymptomatic tags 0 
1-2 indolent fistula, scant drainage, no tenderness 5 
Active fistula, drainage, tenderness, or abscess 10 
Extraintestinal Manifestations 
(Fever > 38.50F for 3 days over past week, definite arthritis, uveitis, E. nodosum, P. 
gangrenosum) 
None 0 
1 5 
> 2 10 
Total Score Possible 110 
Total Score  
Table 2: The Pediatric Crohn’s Disease Activity Index11  
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RESULTS 
 
Patient Enrollment 
 To date, we have enrolled seven patients into the initial study. Of these patients, 
six of them were previously diagnosed with IBD and one was a patient admitted to the GI 
Service for evaluation and management of stomach pain. Four of the patients with IBD 
were diagnosed with UC and 2 patients carried diagnoses of CD. Figure 3 shows these 
enrollment results. 
 This study was approved by the IRB at Boston Children’s Hospital (Protocol 
Number: P00028326). Our plan is to broaden our eligibility criteria to include any patient 
with or without active intestinal inflammation.   This will facilitate study enrollment and 
make possible cross-condition comparisons between groups of patients with active and 
inactive inflammatory (IBD) and non-inflammatory (including constipation and poor 
weight gain ) GI disease. 
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Figure 3: Flowchart of Patient Recruitment. This flow chart represents the current 
population enrolled in the study. We recruited patients that were  admitted to the 
gastrointestinal service at Boston Children’s Hospital. Exclusion criteria included non-
IBD inflammatory disease treatment. 
 
Initial Measurement Ability, Accuracy, and Reliability 
We purchased commercially available redox standard solutions from PCE 
obtained standards with known values of redox potential. We tested our ability to record 
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to reliably measure the value given for the standards. Standard A, reported at 240 mV, 
gave an average value of 238 mV, 238 mV, and 238.3 mV for the Arrowdox, PCE, and 
Redoxsys probes, respectively. Standard B, reported at 468 mV, was read on average as 
471 mV, 461.7 mV, and 478.5 mV for the Arrowdox, PCE, and Redoxsys probes, 
respectively. These values are illustrated in Figure 4. 
 
Figure 4: Standards Measurements Using Redox Probes. Three probes (Arrowdox, 
blue; PCE, green; and Redoxsys, gray) were used to measure the potential of two 
different standards from PCE Instruments™. Standard A was listed as 240 mV. Standard 
B was listed as 468 mV.  Each gave a reading within 10 mV of the listed value. 
0
100
200
300
400
500
600
Standard A (240 mV) Standard B (468 mV)
m
V
Redox Standards
Arrowdox
PCE
Redoxys
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Following confirmation of our ability to use the probes, we created dilution 
curves to test our relative accuracy and reliability. We chose to use apple, orange, and 
cranberry juices because of their their availability and reported  anti-oxidant value12 and 
hydrogen peroxide due to its importance in the oxidant-release pathway of inflammation. 
Figure 5 shows these dilution curves that we created. Redoxsys system, though reported 
to be a reliable measure of redox status within this range of measurements, was not yet 
available in our lab to be used in completion of this assay13. Concentration of redox 
reactants have been previously shown to be inversely measured with voltage; decreasing 
concentrations produce a higher mV14. 
 
A)  
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B)  
 
 
C)  
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Figure 5: Oxidant-Rich Juice Dilution Curves. Serial dilutions (1:2) were made 1:2 in 
distilled water. Increased oxidant concentrations have been shown to lower mV 
readings.14 Two different probes were used to generate data for these dilution curves. The 
sources were: a) Apple Juice, b) Cranberry Juice, c) Orange Juice and d) Hydrogen 
Peroxide. The hydrogen peroxide was obtained as a stabilized substance. 
 
 As Figure 5 demonstrates, we were able to create linear dilution curves for each 
of the three juices. Table 3 shows r2 values obtained from the linear regression of each of 
these dilution curves. As the table and figure demonstrate, hydrogen peroxide did not 
produce a linear curve. This was likely related to the chemical stabilization of the over-
the-counter hydrogen peroxide that was purchased for use in this study. Slopes and Y-
Intercepts from the linear regressions of these curves can be found in Appendix A. 
 
Substance            Arrowdox  
r2 value 
PCE  
r2 value 
Apple Juice 0.9947 0.9925 
Cranberry Juice 0.9512 0.9988 
Orange Juice 0.9968 0.9716 
Hydrogen Peroxide 0.3658 0.5538 
 
Table 3: Linear Regression. This chart includes the r2 values related to the linear 
regression presented in Figure 5.  Curves generated from both Arrowdox and PCE probes 
yielded high r2 values. 
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 Data presented in these figures also demonstrate dilution, or the addition of 
relative high redox potential solution, resulted in a positive linear curve. Readings of a 
lower value indicate a higher level of redox reactants.  
 The Arrowdox and PCE probe measurement yielded different values for each of 
the juices. Since the initial dilution curves were done on different days, new samples of 
juice were obtained to eliminate any discrepancy caused by differences in bottles of juice. 
The PCE device was consistently lower than the Arrowdox, despite both giving similar 
values for the standards obtained. The stabilized hydrogen peroxide, the sample with the 
highest reading, measured on average 398.7 mV on the Arrowdox and 382.3 mV on the 
PCE probe.  These values are comparable in the context of standard deviations from each 
average juice reading was between 0.7-5.3 mV on Arrowdox measurements, and 0.6-22.1 
mV with the PCE machine. We obtained an average measurement of 160 ± 1.4 mV for 
apple juice using Arrowdox and 91.3 ±  1.5 mV with the PCE probe. Cranberry juice was 
measured at  220.5 ± 0.7 mV using Arrowdox and 180 ± 1 mV with the PCE probe. 
Finally, the redox of orange juice was measured at 152 ± 1.4 mV with Arrowdox and 68 
± 8.7 mV with PCE (Figure 6) 
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Figure 6: Comparing the Arrowdox and PCE Probes. The Arrowdox and ORP-14 
sensors were used to measure redox status of different juices and hydrogen peroxide. 
Both devices yielded similar measurements for the stabilized  hydrogen peroxide.  
However the discrepancy between measurement of the redox status of different juices 
was between 50-100 mV. 
  
Measurements of Stool Samples Stored at Room Temperature 
 We measured the redox status of stool samples collected from seven patients over 
a 24-48 hour time period, with sequential  measurements obtained at 0, 2, 4, 6, 8, and 24-
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hour time points. Only one patient  sample was available for analysis at the  48-hour time 
point.  
A)  
 
 
B)  
 
Figure 7: Measurement of Room Temperature Patient Samples Over Time. A) 
Unspun Patient samples stored at room temperature  B) Patient samples supernatants 
stored at room temperature, following centrifugation 
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Unspun samples were stored at room temperature.  The supernatants from spun 
stool samples was collected and stored at room temperature. Figure 7 represents these 
measurements. We observed that both the homogenate and spun samples yielded 
relatively stable readings within the first 8 hours. However, the samples began to exhibit 
slight changes in measurement stability following the 8 hour time point. We also 
observed that, the meausrements obtained from samples at higher mV, (with presumably 
fewer active redox reactants in soluation)  were much more stable and provided  more 
consistent measurements. 
 
Measurements of Stool Samples Stored in Refrigerated Conditions 
 We tested the stability of redox measurement fron stool samples that were 
obtained from  samples stored in a 40C refrigerator. We anticipate that it will be 
impractable to collect fresh stool samples in the ambulatory setting, refrigeration may 
enable study patients to provide clinical samples, provided they are kept at lower ambient 
temperature with a cool pack. Figure 8 shows the results.  
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A)  
 
 
B)  
 
Figure 8: Measurement of Refrigerated Patient Samples Over Time A) Unspun 
Patient samples stored in refrigeration B) Patient samples supernatants stored in 
refrigeration, following centrifugation 
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 Similar to samples stored at room temperature, stool samples that had been 
refrigerated for up to 8 hours exhibited stable redox measurements  This may suggest that  
at least some mediators of redox status  are stable at temperatures between 40C and 250C 
over the first 8 hours after production. However, in contrast to measurements taken from 
stool samples maintained at  room temperature, measurements from  refrigerated samples 
with a negative net ambient redox status (likely higher in mediators of oxidation) did not 
exhibit the same variability as those stored at room temperature. This suggested  that 
storatge at 40C may provide the optimal storage for samples being used to assess redox 
status. 
 
Measurements of Frozen Stool Samples 
We also measured the time course of changes in redox status in freeze-thawed 
stool samples. To this end, amples were successively frozen at 200C at each of various 
time points and then thawed to room temperature before redox measurement. Figure 9 
shows these results. 
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A)  
 
 
B)  
 
 
Figure 9: Measurement of Frozen Patient Samples Over Time A) Unspun Patient 
samples sequentially frozen, thawed, and measured B) Patient samples supernatants 
sequentially frozen, thawed, and measured, following centrifugation 
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Contingent on experimental conditions on a given day, redox measurements from 
stool samples were not always available. Additionally, there was a power failure in the 
laboratory and this resulted precluded redox measurement from the frozen stool sample 
collected from Patient 5. 
Overall redox measurements obtained from frozen stool samples displayed 
increased variability, and this was particularly evident in measurements obtained from 
stool  homogenates. Whereas measurement taken at room temperature  fluctuated in a   
50 mV range, measurements obtained frozen samples varied by to to  100 mV , with 
fluctuations most pronounced  after the four-hour time point.  
 
Analysis of Freezing Effects 
 We compared redox measurements obtained from samples maintained at room 
temperature and from previously  frozen stool samples from each patient. The results can 
be seen in Figure 10. Redox measurements from  frozen stool samples typically higher 
than their room-temperature counterparts. Interestingly, the largest discrepancies were 
within the homogenate. At room temperature stool samples from patients 2, 3, 4, and 6 
each exhibited a redox status well below 0 mV.  However, all of the redox measurements 
obtained from stool samples that had been previously frozen were measured to be higher 
than 0 mV. These results suggest that the oxidant may be unstable during freeze/thaw 
cycles.   
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A)  
 
B)  
 
Figure 10: Effects of Freezing on Patient Sample Measurements A) Unspun Patient 
samples sequentially frozen, thawed, and measured, compared to samples from the 
sample patients stored at room temperature B) A comparison of redox measurements 
obtained from the supernatants of patient samples sequentially frozen, thawed, and 
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measured, following centrifugation, compared to samples from the sample patients stored 
at room temperature (and Appendix A).    
 
Analysis of Centrifuge Effects 
 We next compared the difference between redox measurements obtained from 
homogenized whole-stool samples, in comparison to the supernatants of stool samples 
separated by centrifugation. Figure 11 depicts redox measuements obtained from both 
room temperature and frozen stool specimens. 
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A)  
 
B)  
 
Figure 11: Effects of Centrifugation on Patient Sample Measurements This figure 
compares homogenate samples vs. centrifuged samples, stored a) at room temperature 
and b) by freezing. 
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 Figure 11 shows a loss of reactions due to the centrifugation process. While 
pellets were not measured following centrifugation, this loss could be due either to the 
soluble reactants going into the pellet instead of the supernatant, or that they are unstable 
at high speeds of centrifugation. Additonally, it is important to note that samples were 
centrifuged prior to freezing.  As such, any differences observed in redox measurements  
between the two graphs is likely to be the result of the freezing process and not 
centrifugation. 
 
Pediatric Ulcerative Colitis Activity Index (PUCAI) Scores 
 We recorded the  PUCAI and PCDAI scores for each of the study patients that 
provided a stool sample. These metrics helped determine the level of each  patient’s 
disease activity. We compared the PUCAI and PCDAI scores with the redox 
measurement of contemporaneously collected stool samples. Table 3 reflects these 
measures. 
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Patient Disease Status 
          Patient #                    Diagnosis                       Score               Stool Appearance 
Patient 1 UC 10 Mostly formed 
Patient 2 UC 45 Very bloody 
Patient 3 UC N/A Liquid (Ostomy 
bag) 
Patient 4 CD 15 Mostly liquid, a 
little blood 
Patient 5 UC 20 Slightly liquid 
Patient 6 CD 15 Mostly liquid 
Patient 7 Non-IBD N/A Formed stool 
Table 4: Patient Disease Status We report a patient’s disease status here using the 
qualitative assessment of a PUCAI/PCDAI test to compare with measurements. 
 
As shown in the above figures, patients 2, 3, 4, and 6 exhibited the lowest redox 
measurements. Data from Table 3 demonstrates that these lowest redox measurements 
were obtained from the patients in our study with the most active disease. In contrast, 
redox measurements from stool samples obtained from Patients 1 and 5 (those with the 
least active active IBD), as well as patient 7 (who was not admitted for evaluation and 
management of IBD) were all above 0 mV. This pilot data suggests that changes in 
disease activity/redox mediators may be discernable using the technologies employed in 
this study.   
  
 35 
DISCUSSION 
The results from this small pilot study demonstrate that we are able to reliably 
measure redox status in the stool of patients with and without IBD.  Redox measurements 
in this study were initially obtained using the Arrowdox and  PCE probes. While the 
overall measurements were similar for both devices, they did not overlap. This can be 
further seen in Appendix A, where the slopes of the lines were similar but their Y-
intercepts varied. There are at least two explanations for this disparity.  First, the 
sensitivity of the two probes may be different. The Arrowdox probe has been used before 
in both water treatment studies,15 as well as biological studies analyzing cytochrome 
activity.16 The PCE probe has been used to measure redox status in treated and untreated 
water studies, as well as to to measure stool samples in a recent microbiome study.14 We 
will include  Redoxsys measurements in further experiments. 
The second possibility for the discrepancy between the Arrowdox and PCE 
probes is that that these probes may detect different types of reactants more easily than 
others which could explain the difference in readings. Regardless, the consistency in the 
readings despite the difference is encouraging as we continue to collect and measure. 
Initial studies will be limited to measurement of freshly collected stool samples 
from inpatients.  This will permit the most accurate readings and those likely to be most 
reflective of the  patients’ current physiological condition as it relates to redox status.  In 
addition, measurements from fresh stool samples removes concerns over sample storage. 
Data from the initial condition studies demonstrate that redox measurements are 
comparable from both room temperature and refrigerated samples. 
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The reasons for the effects of freezing remain ambiguous. The samples did not 
appear any different after the freezing process compared to visual observations before 
freezing. This suggests that the loss of signal is not do to some destructuring of the stool. 
Juice samples left out over multiple weeks were measured to be higher to their initial 
readings. This suggests a reactant stability that is good in the short term but makes long 
term-storage difficult. The freezing process has been shown to damage some biological 
markers in stool samples,17,18 but not all, including DNA.19 Interestingly, antioxidants 
have been shown to have a beneficial effect against crypreservation-induced oxidative 
stress in cells.20 This study used melatonin, a known antioxidant, to reduce the harmful 
effects of oxidative stress during the freezing process.20 This suggests that perhaps some 
interaction between antioxidants and the ROS is either induced or increased during the 
freezing process, resulting in degredation of redox reactants. 
Analyzing the dilution curve for the juices, we can see how their anti-oxidant 
properties may or may not impact on oxidant reading. While cranberry juice is reported 
to contain considerable  anti-oxidants,13  it gives off the weakest of the three juice redox 
readings (Figure 5). We may therefore find that anti-oxidant capacity will be better 
defined functionally, as we measure its ability to neutralize ambient oxidant species in 
solution.  Antioxidants may not be reflexted in baseline/resting redox status of a 
particular solution.    
Dietary antioxidant intake may explain some inter-patient  variability.  Our initial 
hypothesis suggested that we look at dietary changes to understand how diet affects their 
fecal redox status. This could potentially help to explain why a group of patients with 
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high antioxidant intake may present with disproportionately high redox status relative to 
the clinical disease activity.21  However, the second outcome is that this technology may 
also better inform our understanding of how antioxidant rich foods can be rationally 
included in the medical treatment of IBD. We know that ingesting certain fruits and 
vegetables can have great health benefits especially against diseases with unknown 
treatment paths like Alzheimer’s.22 Anti-oxidant-related treatments have been a popular 
topic in IBD research.23 We will be assessing anti-oxidant intake in this study through the 
use of a standardized a short dietary questionnaire, which we have adapted from one done 
by Satia et al. in 2009.24 The questionnaire can be found in Appendix B. 
We will have to consider  other factors that could affect redox measurements and 
skew results. The gut microbiota has been shown to play an important role in disease 
states and strategies addressing the microbiota have been used successfully in animal 
models of IBD.25 However, while its role can be an oxidative, the gut microbiota has 
been implicated as both oxidant and anti-oxidant, and this will likely have to be better 
understood as we measure redox levels from patient to patient.26  
The measurement of redox status may be relevant in other organ systems and 
bodily fluids including the blood and urine.   Similary to stool redox measurement, 
changes in redox status in urine have been unexplored to date. We are in the process of 
finalizing an industry collaboration to assist in the assessment of urinary markers of 
oxidant species. We will assess changes in redox status in whole blood and serum 
samples using both the Arrowdox and Redosys systems.27 
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Further questions persist as we continue to collect samples. The relative 
geography of redox status along the length of the GI tract, both in health and in disease 
states, has yet to be mapped.  Therefore, measuring samples taken from different areas of 
the small and large intestine could help provide answers as not only to how redox 
production may change, but to better understand how localized changes may impact on  
global/systemic redox status. Previous similar studies have looked at effects of a 
fermentation on the gut microbiota in different areas along the GI tract.28 Gut microbiota 
have been shown to have a strong association with redox status and ROS 
production/destruction.29 Changes to the lining of the small and large intestine could 
result in an assymmetric breakdown of the membrane phospholipids, and thereby provide 
fodder for the development of discrete oxidant species.  
Finally, our current results are confined to inpatient enrollment due to the 
condition tests. As we establish a protocol and optimal storage and performance 
standards,  we can begin to analyze samples obtained from patients in the outpatient 
setting. Not only will this provide us with the abtility to see how inactive IBD patients 
compare, but it will also allow this study to complete a longitudinal analysis of individual 
patients by following their samples over time, thereby allowing  them to act as their own 
controls.  
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CONCLUSION 
 The findings presented here demonstrate the ability to reliably measure redox 
status in the stool of patients with IBD. Furthermore, condition studies have demonstrated 
that stool samples that have been kept at room temperature or refrigerated provide the 
most consistent and reliable redox measurements . 
 Stool redox measurements measured in patients with active IBD were quite 
different from measurements obtained in patients with inactive disease.  However, with 
only one  control patients has been included in this analysis to date and a much larger 
sample size will be necessary to draw more definitive conclusions.   Nonetheless, these 
preliminary data support the need for larger ongoing studies to better define the potential 
utility of this novel technology in the evaluation of patients with inflammatory and non-
inflammatory GI disease 
  
  
 40 
Appendix A: Slopes and Y-Intercepts of Oxidant-Rich Sources 
These charts represent the equations from linear regression of the dilution curves created 
with different oxidant rich sources. A) Slope B) Y-Intercept 
 
A) 
Substance            Arrowdox  
Slope 
PCE  
Slope 
Apple Juice 23 20.733 
Cranberry Juice 8.533 5.7333 
Orange Juice 27.633 26.767 
Hydrogen Peroxide 13.6 24.467 
 
 
B)  
Substance            Arrowdox  
Y-Intercept 
PCE  
Y-Intercept 
Apple Juice 234.33 398.67 
Cranberry Juice 336.5 5.7333 
Orange Juice 220.67 70.167 
Hydrogen Peroxide 370.33 46.833 
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Appendix B: Room Temperature vs. Frozen Storage By Patient Over Time 
These charts expands on Figure 10 by comparing frozen vs. refrigerated vs room 
temperature readings over time for each sample. A) Patient 1 Homogenate B) Patient 1 
Spun C) Patient 2 Homogenate D) Patient 2 Spun E) Patient 3 Homogenate F) Patient 3 
Spun G) Patient 4 Homogenate H) Patient 4 Spun I) Patient 5 Homogenate J) Patient 5 
Spun K) Patient 6 Homogenate L) Patient 6 Spun M) Patient 7 Homogenate N) Patient 7 
Spun (note: patient 5’s frozen samples were lost) 
A)  
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B)  
 
C)  
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D)  
 
E)  
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F)  
 
G)  
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H)  
 
I)  
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J)  
 
K)  
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L)  
 
M)  
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N)  
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Appendix C: Dietary Questionnaire 
 
 
Patient Questionnaire 
Part 1: Diet 
A) Specific Foods 
 How often do you eat during a typical week 
3-7 times per week 1-2 times per week Rarely Never 
Fruits and Vegetables 
1) Apples m m m m 
2) Applesauce m m m m 
3) Bananas m m m m 
4) Cherries m m m m 
5) Oranges m m m m 
6) Peaches m m m m 
7) Pineapple m m m m 
8) Strawberries m m m m 
9) Blueberries m m m m 
10) Raspberries m m m m 
11) Blackberries m m m m 
12) Grapes m m m m 
13) Raisins m m m m 
14) Avocado m m m m 
15) Bell Pepper m m m m 
16) Carrots m m m m 
17) Celery m m m m 
18) Corn m m m m 
19) Green Beans m m m m 
20) Peas m m m m 
21) Tomatoes m m m m 
22) Apricots m m m m 
23) Grapefruit m m m m 
24) Kiki m m m m 
25) Mango m m m m 
26) Papaya m m m m 
27) Plums m m m m 
28) Pears m m m m 
29) Brussel Sprouts m m m m 
30) Cabbage m m m m 
31) Jalapeños m m m m 
32) Mixed Vegetables m m m m 
33) Squash m m m m 
34) Zucchini m m m m 
Meats 
35) Fish m m m m 
36) Beef m m m m 
37) Deli Meats m m m m 
38) Eggs m m m m 
Other 
39) Peanut Butter m m m m 
40) Oatmeal m m m m 
41) Coleslaw m m m m 
42) Chili m m m m 
43) Macaroni and Cheese m m m m 
44) Pizza (Slice) m m m m 
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B) Categorical Foods (Select All that Apply) 
 
(Select All That Apply) How Often Do You Eat? 
3-7 times per week 1-2 times per week Rarely Never 
45) Small Citruses 
m Clementines 
m Mandarins 
m Nectarines 
m Tangerines 
m m m m 
46) Melons 
m Cantelope 
m Honeydew 
m Watermelon 
m m m m 
47) Stalks 
m Broccoli 
m Cauliflower 
m m m m 
48) Spinach 
m Cooked 
m Raw 
m m m m 
49) Lettuce 
m Iceberg 
m Romaine 
m Other 
m m m m 
50) Onions 
m Onion 
m Leaks 
m Scallions 
m m m m 
51) Potatoes 
m Regular  
m Sweet Potato 
m Yams 
m m m m 
52) Greens 
m Collard Greens 
m Kale 
m m m m 
53) Nuts 
m Peanut 
m Almond 
m Other 
m m m m 
54) Cereal 
m Raisin Bran 
m Cheerios 
m Other 
_________ 
 
m m m m 
55) Bread 
m White 
m Whole Wheat 
m m m m 
56) Cheese 
m Slices/Sticks 
m Cottage 
m Cream Cheese 
m m m m 
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(Select All That Apply) How Often Do You Eat? 
3-7 times per week 1-2 times per week Rarely Never 
57) Milk 
m Skim 
m Reduced Fat 
m Whole 
m Almond 
m Soy 
m m m m 
58) Juices 
m Apple 
m Carrot 
m Cranberry 
m Grapefruit 
m Grape 
m Orange 
m Pineapple 
m Tomato 
m Fruit Punch 
m Other: 
 
 
m m m m 
59) Tea (Iced/Hot) 
Types: ________ 
 
m m m m 
60) Pasta 
(select common): 
m Red sauce 
m White sauce 
m Cheese 
m m m m 
61) Soup 
m Minestrone 
m Tomato 
m Vegetable 
m m m m 
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Part 2: Medication 
A) Supplements 
Supplement Type/Dose How often do you take this 
during a typical week 
62) Multivitamin 
 
m I do not take a multivitamin 
(move to #63) 
m Centrum 
m NatureMade Multivitamin  
m One-A-Day  
m Kirkland Multivitamin 
m Flintstones 
m Other (please specify): 
____________________ 
 
m Rarely 
m 1-3 
m 4-6 
m Daily 
63) Vitamin A 
 
m I do not take Vitamin A 
(move to #64) 
m 5,000 IU 
m 7,500 IU 
m 10,000 IU 
m 15,000 IU 
m 20,000 IU 
m Unsure 
m Rarely 
m 1-3 
m 4-6 
m Daily 
64) Vitamin B12 
 
m I do not take Vitamin B 
(move to #65) 
m 500 mcg 
m 1,000 mcg 
m 3,000 mcg 
m 5,000 mcg 
m 25,000 mcg 
m Unsure 
m Rarely 
m 1-3 
m 4-6 
m Daily 
65) Vitamin C 
 
m I do not take Vitamin C 
(move to #66) 
m 60 mg 
m 100 mg 
m 250 mg 
m 500 mg 
m 1,000 mg 
m 1,500 mg 
m Unsure 
m Rarely 
m 1-3 
m 4-6 
m Daily 
66) Vitamin D 
 
m I do not take Vitamin D 
(move to #67) 
m 400 IU 
m 1,000 IU 
m 2,000 IU 
m 5,000 IU 
m 10,000 IU 
m Unsure 
m Rarely 
m 1-3 
m 4-6 
m Daily 
67) Vitamin E 
 
m I do not take Vitamin E 
(move to #68) 
m 30 IU 
m 100 IU 
m 200 IU 
m 400 IU 
m 600 IU 
m Unsure 
m Rarely 
m 1-3 
m 4-6 
m Daily 
68) Fish Oil 
 
m I do not take Fish Oil    
(move to #69) 
m 1,000 mg 
m 1,200 mg 
m 2,400 mg 
m Unsure 
m Rarely 
m 1-3 
m 4-6 
m Daily 
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B) Over the Counter Medication 
Medicine 
 
Dose Dose/Tabs How often do you take 
this during a typical week 
69) Acetaminophen 
(Tylenol) 
 
m I do not take acetaminophen 
(move to #70) 
m Children’s (80/160 mg) 
m Regular (325 mg) 
m Extra-Strength    
(500/650 mg) 
m Unsure 
m 1 pill 
m 2 pills 
m 3 pills 
m < 1 per week 
m 1-3 
m 4-6 
m Daily 
m More than once a day 
70) Ibuprofen 
(Advil/Motrin) 
 
m I do not take ibuprofen 
m Children’s (50/100 mg) 
m Regular (200 mg) 
m Extra-Strength (400 mg) 
m Unsure 
m 1 pill 
m 2 pills 
m 3 pills 
m < 1 per week 
m 1-3 
m 4-6 
m Daily 
m More than once a day 
 
Thank you! 
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